Wednesday, October 06, 2021 8:34:18 AM
Acasti Pharma, Inc.
Wed, October 6, 2021, 8:30 AM
Patents strengthen Acasti’s IP portfolio and provide protection through 2036 and 2037, respectively
LAVAL, Québec, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announces that the European Patent Office, Chinese Patent Office and the Mexican Patent Office have issued composition of matter patents for GTX-101, a novel bio-adhesive film forming topical spray formulation of bupivacaine for the treatment of Postherpetic Neuralgia (PHN). PHN is a persistent and often debilitating neuropathic pain caused by nerve damage from the varicella zoster virus (shingles), which may persist for months and even years. GTX-101 could provide significant benefits over the current standard of care including greater convenience, faster onset of action and longer duration of pain relief. The granted patents are valid until 2036.
In addition, the Japanese Patent Office has granted a composition of matter patent for GTX-102, a novel, easy-to-use oral mucosal spray formulation of betamethasone, intended to improve neurological symptoms of Ataxia-telangiectasia (A-T). A-T is a progressive, neurodegenerative genetic disease that primarily affects children causing severe physical disability, for which no treatment currently exists. The granted patent is valid until 2037.
Jan D’Alvise, Chief Executive Officer of Acasti, stated, “These latest patents are important additions to our intellectual property portfolio, expanding product protection to additional important international markets as we continue to progress these drug candidates through clinical studies. We believe these granted composition of matter patents further support the commercial potential of GTX-101 and GTX-102. Both drug candidates have already received Orphan Drug Designation from the FDA and could address important underserved global markets. The goal of these proprietary formulations is to improve the quality of care and patient outcomes by providing significant efficacy, safety and convenience benefits including ease of use, faster onset of action and extended relief.”
https://finance.yahoo.com/news/acasti-pharma-awarded-composition-matter-123000390.html
Recent ACST News
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 09/06/2024 08:07:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 08:05:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/09/2024 12:00:29 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/09/2024 11:30:40 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 08/07/2024 08:14:52 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/05/2024 04:15:03 AM
- Form S-4/A - Registration of securities, business combinations: [Amend] • Edgar (US Regulatory) • 07/31/2024 11:22:52 AM
- Form SC 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 07/11/2024 01:10:22 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2024 11:19:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2024 11:19:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2024 11:19:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2024 11:18:46 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/08/2024 11:18:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 01:00:13 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/12/2024 12:30:29 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2024 12:30:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 09:08:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 09:08:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/20/2023 09:05:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2023 12:30:09 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM